Cover Image
市場調查報告書

Entecavir的中國市場分析 (2010∼2019年)

Investigation Report on China Entecavir Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 333477
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Entecavir的中國市場分析 (2010∼2019年) Investigation Report on China Entecavir Market, 2010-2019
出版日期: 2015年06月18日 內容資訊: 英文 30 Pages
簡介

中國國內的B型肝炎病毒 (HBV) 感染者達到1億人以上,其中2000∼3000萬人的慢性B型肝炎發病。慢性B型肝炎原因的死亡人數達到每年50萬人,發生1000億人民幣的社會損失。作為脫氧鳥苷口服藥之一的Entecavir,有所謂抗病毒性高,效驗很快,副作用較低的特性。2005年5月受FDA (美國食品藥物管理局) 認證,從2006年初開始中國國內也上市。2006年為3000萬人民幣的銷售額,以55%年複合成長率(CAGR) 成長,2014年達到12億700萬人民幣。

本報告提供中國的Entecavir的市場相關分析、整體市場規模和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來市場趨勢預測等調查評估。

第1章 Entecavir的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Entecavir市場概況

  • 中國國內的依那西普(Etanercept)專利的申請、認證情形
  • 主要製造商
  • 市場規模

第3章 Entecavir銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的Entecavir市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的Entecavir市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 Entecavir的醫院用標準價格

第7章 中國國內的Entecavir的主要製造商

  • Sino-American Shanghai Squibb Pharmaceuticals Ltd
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • Jiangxi Qingfeng Pharmacy Co., Ltd
  • Fujian Cosunter Pharmaceutical Co., Ltd
  • Dawnrays Pharmaceutical Limited

第8章 中國的Entecavir市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506219

The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.

Entecavir, an oral drug of oral deoxyguanosine, was developed by Bristol-Myers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA's approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent. According to CRI's market survey, the annual sales value of entecavir in China rose from CNY 30 million in 2006 to CNY 1.207 billion in 2014 and CAGR during this period reached up to 55%. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 60% in 2014 for sales value and over 50% for sales volume.

Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug's entering into the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape. Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.

Readers can get at least the following information from this report:

  • market size of entecavir in China
  • competitive landscape of entecavir in Chinese market
  • price of entecavir made by different manufacturers in China
  • market outlook of entecavir in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-HBV drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

Table of Contents

1. Related Concepts of Entecavir

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Entecavir in China

  • 2.1. Patent and Approval Status of Entecavir in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Entecavir in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Entecavir in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Entecavir in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Entecavir in China in 2014

  • 6.1. Sino-American Shanghai Squibb Pharmaceuticals Ltd (Trade Name: Baraclude)
  • 6.2. Sichuan Haisco Pharmaceutical Co., Ltd (Trade Name: Gan Bei Qing)
  • 6.3. Shandong Lukang Pharmaceutical Co., Ltd (Trade Name: Mu Chang)
  • 6.4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Run Zhong)
  • 6.5. Jiangxi Qingfeng Pharmacy Co., Ltd (Trade Name: Wei Li Qing)
  • 6.6. Fujian Cosunter Pharmaceutical Co., Ltd (Trade Name: En Gan Ding)
  • 6.7. Dawnrays Pharmaceutical Limited (Trade Name: Leiyide)

7Major Manufacturers of Entecavir in Chinese Market, 2010-2014

  • 7.1. Sino-American Shanghai Squibb Pharmaceuticals Ltd
  • 7.2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • 7.3. Jiangxi Qingfeng Pharmacy Co., Ltd
  • 7.4. Fujian Cosunter Pharmaceutical Co., Ltd
  • 7.5. Dawnrays Pharmaceutical Limited

8. Market Outlook of Entecavir in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Entecavir in China
  • Chart Approval Information of Entecavir in China
  • Chart Sales Status of Entecavir in China, 2010-2014
  • Chart Sales Value of Entecavir in China, 2010-2014
  • Chart Sales Value of Entecavir in Some Regions in China, 2010-2014
  • Chart Sales Volume of Entecavir in China, 2010-2014
  • Chart Market Share of TOP5 Manufacturers of Entecavir for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Shanghai Squibb in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Chia Tai Tianqing in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Dawnrays in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Jiangxi Qingfeng in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Fujian Cosunter in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Made by Other Manufacturers in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Capsules in China, 2010-2014
  • Chart Sales Value and Market Share of Entecavir Tablets in China, 2010-2014
  • Chart Price of Entecavir Made by Sino-American Shanghai Squibb Pharmaceuticals Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Sichuan Haisco Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Shandong Lukang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Jiangxi Qingfeng Pharmacy Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Fujian Cosunter Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Entecavir Made by Dawnrays Pharmaceutical Limited in Some Chinese Cities in 2014
Back to Top